Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VNZZZ
ADC Name
PF-06688992
Synonyms
GD3 ADC; PF 06688992; PF-06688992; PF06688992
   Click to Show/Hide
Organization
Pfizer Inc.; Memorial Sloan-Kettering Cancer Center
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Melanoma
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Ganglioside GD3
  Antigen Info 
Payload Name
PF-06464368
  Payload Info 
Therapeutic Target
Unclear
Linker Name
Undisclosed
Conjugate Type
Undisclosed
Puchem SID
402426011 , 472420097 , 440234698
TTD ID
D0JB9C
ChEBI ID
CHEMBL4594487
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03159117
Phase 1
A phase 1 open-label dose escalation of GD3 ADC (PFIZER PF-06688992) in subjects with unresectable stage 3 or stage 4 malignant melanoma (b802wi209568).
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT03159117  Clinical Status Phase 1
Clinical Description A phase 1 open-label dose escalation of GD3 ADC (PFIZER PF-06688992) in subjects with unresectable stage 3 or stage 4 malignant melanoma (b802wi209568).
References
Ref 1 A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568), NCT03159117